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Disruption of iron homeostasis and increased glial response are known to occur in
brains afflicted by Alzheimer’s disease (AD). While the APP/PS1 transgenic mouse model
recapitulates the hallmark amyloid-beta plaque pathology of AD, it does so in a different
neuronal mileu than humans. Understanding the iron characteristics and glial response of
the APP/PS1 model is important when testing new treatment procedures and translating
these results. Brain tissue from AD patients, APP/PS1 mice, and controls were stained
for iron, H- and L-ferritin, microglia, astrocytes, Aβ40/42, and degenerating neurons.
The histological data demonstrate differences in ferritin, iron distribution, gliosis, and
Aβ plaque composition between APP/PS1 and AD tissue. Specifically, an association
between focal iron deposition and Aβ plaques is found ubiquitously throughout the
AD tissue and is not observed in the APP/PS1 mouse model. Ferritin, microglia,
and astrocyte staining show differential response patterns to amyloid plaques in AD
and the APP/PS1 tissue. Aβ 40 and 42 antibody and thioflavin staining demonstrate
morphological differences in plaque composition. The histological data support the
hypothesis that iron distribution, iron management, and glial response histologically differ
between the APP/PS1 and AD brain. Acknowledging the caveat that there are distinct
plaque, iron, and glial contrasts between the AD brain and the APP/PS1 mouse is crucial
when utilizing this model.
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Introduction
The extracellular formation of amyloid-beta (Aβ) protein plaques is a major defining
neuropathological characteristic of Alzheimer’s disease (AD). It is evident that amyloid formation
is involved and relevant in the disease process as plaques are found ubiquitously in AD patients’
cortical tissue (Hardy and Selkoe, 2002). Consequently, transgenic mouse models have been
developed to mimic the formation of Aβ plaques within neural tissue (Borchelt et al., 1996,
1997) and are especially important for understanding disease etiology and testing new therapeutic
procedures (Siman et al., 2000; Jankowsky et al., 2001; Dewachter et al., 2002; Richards et al., 2003;
Casas et al., 2004). These specific transgenic mice harbor chimeric mouse/human familial AD genes
for amyloid precursor protein (APP) and a mutant human presenilin 1 (PS1) under control of the
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mouse prion promoter. The mice develop fibrillar Aβ plaques
at approximately 9 months of age and subsequently do so
progressively throughout their lifespan.
An important histopathologic aspect of Aβ plaques is their
co-localization with focal iron deposition (Smith et al., 1996;
Lovell et al., 1998). A relationship between iron and amyloid
plaques has been established in AD tissue (Smith et al., 1997;
Collingwood et al., 2008; Meadowcroft et al., 2009; Ayton et al.,
2013) and, to a lesser extent, in the APP/PS1 model (Jack et al.,
2004; El Tannir El Tayara et al., 2006; Meadowcroft et al., 2009;
Chamberlain et al., 2011; Wengenack et al., 2011; Wadghiri
et al., 2012; Bourassa et al., 2013). Iron is an essential element
required as a cofactor for numerous metabolic processes due
to its ability to receive and donate electrons during redox
cycling. Homeostasis of iron is tightly regulated under normal
physiological conditions as excessive amounts of iron are known
to cause cellular susceptibility to oxidative stress. Accumulation
of iron throughout cortical tissue and focal deposition within Aβ
plaques are both known to occur within the AD brain (Connor
et al., 1992a). In addition, altered regulation of iron management
proteins are observed around Aβ plaques and in AD cortical
tissue. Specifically, robust staining of intracellular ferritin and
extracellular transferrin is observed in the vicinity and periphery
of AD Aβ plaques (Connor et al., 1992b). The data strongly
suggest that there is a disruption in brain iron homeostasis
associated with AD and that the misregulation of iron plays a
central role in disease pathology.
Microglial (Benveniste et al., 2001; von Bernhardi and
Ramirez, 2001; Lopes et al., 2008) and astrocyte (Schubert et al.,
2009) involvement are known to occur in the AD brain and
have also been reported in the APP/PS1 mouse brain (Wegiel
et al., 2001, 2003). Upregulation of microglia and astrocyte
cells are observed in the AD brain and both are involved in
iron homeostasis. Microglia participate in neuronal maintenance
and protection via the sequestration of excessive iron within
ferritin. The incidence of L-ferritin positive active microglia is
significantly increased in the AD brain and the characterization
of L-ferritin positive cells has shown that they are almost
exclusively microglial in nature based on morphological and
immunohistochemical (IHC) staining (Jellinger et al., 1990;
Connor et al., 1992b; Lopes et al., 2008). An increase in
filamentous astrocytes, indicative of activation, is found within
AD neural tissue. In addition, astrocyte activation and the
astrocyte induced release of reactive oxygen species is mediated
by the presence of Aβ in cultured cells (Schubert et al., 2009).
The role of iron misregulation and the ensuing inflammatory
response has not been fully elucidated in AD or in the amyloid-
generating transgenic mouse models. An animal model that
accurately reproduces all characteristics of AD pathology has
not been created. Nevertheless, these models are routinely used
to study methods of plaque clearance and iron chelation with
pharmacological or biochemical interventions (Malm et al., 2012;
Guo et al., 2013a; Hajos et al., 2013; Mengel et al., 2013).
Investigation of the similarities and differences in the AD and
transgenic model brain tissue is essential in understanding how
best to use them for AD studies (Woodhouse et al., 2009). With
divergent amyloid production processes occurring between the
Alzheimer’s and APP/PS1 brain tissue, a histological comparison
of iron distribution and inflammatory glial response in relation
to Aβ plaques within the APP/PS1 transgenic model is important
to describe their pathogenic likeness to AD.
In this report, we have undertaken a research design
which simultaneously incorporates various histological staining
techniques on the same set of tissue samples from the APP/PS1
transgenic mouse model, AD brains, and age-matched controls.
Our results provide new information on iron association,
inflammatory response, Aβ plaque morphology, and related
neurodegeneration in AD and APP/PS1 brain tissue samples
which allow us to examine the hypothesis that iron regulation
and the associated inflammatory response contrasts between the
APP/PS1 and AD brain in these aspects. The data demonstrates
that there is a divergence in Aβ plaque iron composition and
glial response between the AD and APP/PS1 brain tissue. The
rationale for this separation is discussed in regard to brain milieu,
glial response, and plaque formation.
Materials and Methods
Alzheimer’s and Control Brain Samples
Entorhinal cortex (Brodmann area 28/34) brain tissue samples
fromAD subjects (n = 5) and age-matched controls (n = 3) were
obtained with consent and utilized following The Pennsylvania
State—College ofMedicine Institutional Review Board guidelines
(Harvard Brain Tissue Resource Center, McLean Hospital,
Belmont, MA) (Demographics in Table 1). Analysis of the tissue
indicated that AD tissue samples were highly positive for Aβ
plaques and neural fibrillary tangle staining, consistent with a
postmortem diagnosis of Braak stage VI (Braak and Braak, 1991;
Braak et al., 2006). There was not a significant difference between
subjects’ age at time of death with Alzheimer’s patients averaging
73.6 ± 2.9 years and control patients averaging 75.6 ± 2.9 years.
The postmortem interval (PMI) between time of death and tissue
harvesting was longer for controls (29.0 ± 1.3 h) compared to
Alzheimer’s patients (17.3 ± 2.0 h), p < 0.01. Tissue dissected
from the entorhinal cortex was fully immersion fixed in 4%
paraformaldehyde in pH 7.3 phosphate buffered saline (PBS) for
48 h. Tissue samples were cryogenically protected through 10,
20, and 30% sucrose gradients in deionized water (dH2O) for
48 h each. Five coronal tissue sections were cut at 16µm per
entorhinal cortex specimen per staining protocol on a cryostat,
mounted on poly-lysine and gelatin coated slides, heated to 50◦C
to adhere samples to slides, and prepared for histological staining
according to individual protocols as described below.
Statement of Ethical Approval
All protocols were approved by The Pennsylvania State
University - College of Medicine Institutional Animal Care and
Use Committee (IACUC).
APP/PS1 and Control Mice
Transgenic mice (n = 5) inserted with a chimeric mouse/human
APP (APPSwe695, K595N and M596L mutations) and a mutant
human PS1 (PS1-1E9) (Borchelt et al., 1996, 1997) were obtained
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TABLE 1 | Summary of Alzheimer’s disease and control patient
demographics.
Patient type Age Sex Braak stage PMI
Human—Alzheimer’s 72 Male VI 24.13
75 Male VI 15.58
70 Male VI 11.83
84 Female VI 16.83
67 Male VI 18.42
Human—Control 70 Male – 29.36
80 Female – 26.67
77 Male – 31.16
PMI, post mortem interval (hours).
commercially from The Jackson Laboratory [strain name B6C3-
Tg (APPswe,PSEN1dE9)85Dbo/J, stock number 004462].
Animals were kept in the animal facility under veterinary
care with normal feeding, light, and handling conditions. All
protocols were approved by the Institutional Animal Care
and Use Committee. Age-matched non-carrier mice (n = 4)
were used as controls. After aging naturally until 24 months
old, animals were euthanized via an intra-peritoneal injection
of sodium pentobarbital (200mg/kg) and were transcardially
perfused with cold Lactated Ringer’s solution (pH 7.4), followed
by buffered 4% paraformaldehyde in PBS.Whole brain tissue was
harvested and placed in pH 7.3 buffered 4% paraformaldehyde
for 48 h to allow full tissue fixation. The tissue was cryo-
protected in sucrose, cut coronally on a cryostat at approximately
Bregma −1.0mm, and prepared in the same fashion as human
sections.
Iron and Amyloid Staining
Tissue sections were co-stained for iron and fibrillar Aβ with
a 3,3′-diaminobenzidine tetrahydrochloride (DAB) enhanced
Perl’s Prussian blue stain, followed by an aqueous thioflavin-
S stain according to previous methods (Meadowcroft et al.,
2009). In brief, mounted tissue sections were rinsed in dH2O
for 15min, placed in equal volumes of freshly prepared 4%
potassium ferrocyanide (P236, Fisher Scientific, Waltham, MA)
and 4% hydrochloric acid (HCl) (final combined concentrations
2% for each) for 30min, followed by two 5min rinses in dH2O.
Intensification of the iron stain was performedwith 5min of DAB
counterstaining (D5637, Sigma, St. Louis, MO) (10mg dissolved
in 15ml of PBS with 16µl of 30% H2O2) followed by two
5min rinses in dH2O. Tissue samples were then placed in 1%
thioflavin-S (T1892, Sigma, St. Louis, MO) aqueous solution for
5min, followed by differentiation in 70% ethanol for 5min and
two 5-min washes in dH2O. To preserve fluorescence, sections
were covered with aqueous mounting media and cover slipped.
To test for the possibility of confounding interactions between
methods during co-staining; each stain was tested on separate
tissue samples to determine their individual efficacy compared
to the co-stained sections. The results of this test indicated no
adverse interaction between selected stain pairings. In addition,
tissue sections placed in DAB alone demonstrated there was no
binding of the compound to Aβ plaques. A modified Perl’s stain
(LeVine, 1991, 1997) with proteinase K was used to visualize
minute amounts of iron within the amyloid masses. Tissue
sections were hydrated in PBS for 15min followed by immersion
in sodium borohydride (10mg/ml PBS, 213462, Sigma, St. Louis,
MO) for 30min. Sections were then rinsed in PBS twice for
5min and immersed in proteinase K (30µg/ml, P6556, Sigma, St.
Louis, MO) and 0.01% Triton X-100 in PBS for 20min. Next, the
sections were placed in a solution of 1% hydrochloric acid, 1%
potassium ferrocyanide, and 1% Triton X-100 in distilled water
for 30min. Amplification of the iron staining was accomplished
with 0.5mg/ml DAB and 2µl/ml of 30% hydrogen peroxide in
pH 7.6 0.05MTris HCl for 15min. The sections were rinsed twice
for 5min in dH2O, stained with thioflavin-S aqueous solution
for 5min, differentiated in 70% ethanol for 5min, and finally
underwent two 5min dH2O rinses before being mounted on
slides and cover slipped.
Immunohistochemistry Staining
Air dried tissue sections were placed in 95◦C citrate buffer
(10mM sodium citrate tribasic dehydrate, 0.05% Tween 20 in
dH2O, pH 6.0) for 15min. Slides were rinsed three times with
PBS for 5min each, then nonspecific protein binding was blocked
by 30min incubation with 1% bovine serum albumin (BSA) in
1x PBS Tween (PBST). Sections were incubated with primary
antibodies at their respective dilution factors in 1% BSA in 1x
PBST overnight in an airtight incubation-humidity chamber.
After primary incubation, the antibody was decanted and slides
were rinsed in PBS three times for 5min each. Sections were
incubated with fluorescent secondary antibodies (Alexa Fluor,
Invitrogen, Carlsbad, CA) in 1% BSA in 1x PBST for 2 h in a
humidity chamber. The secondary antibody was then decanted
and slides were rinsed in PBS three times for 5min each, followed
by mounting, and cover-slipping.
For Aβ40 staining, a mouse monoclonal beta Amyloid 1-40
antibody [BAM-10] (1/100, AB7501, Abcam Inc., Cambridge,
MA) was used followed by an anti-mouse red fluorescent
Alexa Fluor 555 IgG (A-21422) secondary antibody. Following
secondary incubation and PBS rinsing, tissue sections were co-
stained with 1% thioflavin-S for 10min, differentiated in 70%
ethanol, washed twice in dH2O, mounted, and cover-slipped.
For Aβ42 staining, a rabbit polyclonal beta Amyloid 1-42
antibody (1/200, AB10148, Abcam Inc., Cambridge, MA) was
used followed by an anti-rabbit red fluorescent Alexa Fluor 555
IgG (A-21428) secondary antibody. Tissue sections were then
co-stained with thioflavin-S according to the method outlined
above.
To stain for light-ferritin (L-) polypeptides, a mouse
monoclonal ferritin light chain (D-9) antibody (1/125, SC-74513,
Santa Cruz Biotechnology, Santa Cruz, CA) was used followed
by Alexa Fluor 555 IgG (A-21422) secondary antibody. Heavy-
Ferritin (H-) polypeptides were stained with a rabbit polyclonal
ferritin heavy chain (H-53) antibody (1/125, SC-25617, Santa
Cruz Biotechnology, Santa Cruz, CA), followed by Alexa Fluor
555 IgG (A-21428) secondary antibody. Tissue sections were
co-stained with thioflavin-S to stain for fibrillar Aβ deposits.
To stain for microglial cells, a rabbit Anti IBA-1 (Ionized
calcium binding adaptormolecule 1) antibody (1/500, 019-19741,
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Wako Chemicals USA, Inc., Richmond, VA) was used, followed
by incubation with Alexa Fluor 555 IgG (A-21428) secondary
antibody. Thioflavin-S was used as a co-stain for fibrillar Aβ after
antibody staining.
To distinguish astrocytes, a polyclonal chicken anti-glial
fibrillary acidic protein (GFAP) antibody (1/250, AB5541,
Millipore, Billerica, MA) was used, followed by Alexa Fluor
555 anti-chicken IgG (A-21437) secondary antibody incubation.
Tissue sections were then stained with thioflavin-S for fibrillar Aβ
visualization.
Fluoro-Jade C Staining
A Fluoro-Jade C (FJC) stain was utilized along with
immunohistological antibody staining to identify degenerating
neuronal cells and their relation to Aβ plaques. Sections were
stained with Aβ40 specific primary antibodies, followed by Alexa
Fluor 555 secondary antibody according to the procedure above
and then rinsed twice for 5min in PBS. Slides were then rinsed
in dH2O for 2min followed by immersion in 0.06% potassium
permanganate for 10min and a subsequent rinse for 2min in
distilled water. Slides were immersed in 0.0001% FJC (AG325,
Millipore, Billerica, MA) solution for 10min, followed by three
1min rinses in dH2O. Slides were then air dried for 30min at
50◦C followed by immersion in xylene dehydration, mounted,
and cover-slipped. The exact mechanism by which Fluoro-Jade
works has not been resolved, however it is hypothesized that
the highly poly-anionic fluorescein derivative binds to a specific
apoptotic molecule which is expressed by damaged neuronal
cells (Schmued et al., 2005).
Microscopy
High resolution microscopy of cortical gray matter regions of
interest in the tissue sections was performed using a Nikon
OptiPhot microscope and Nikon Digital Sight camera using
NIS-Elements software. Bright-field under the visible light
spectra and phase contrast using a phase contrast objective and
condenser were used to view iron stains. A FITC fluorescence
cube at 495 nm excitation and 520 nm emission (Nikon B-22)
was used to visualize thioflavin-S positive Aβ deposits and FJC
stains. A Nikon G-2A filter cube at 550 nm excitation and at
570 nm emission was used to visualize the Alexa Fluor 555
secondary antibody.
Results
IBA-1 positive microglial cells in human AD (Figure 1A) show
microglia morphologically in both ramified and active states
throughout the tissue samples. Thioflavin-s staining (Figure 1B)
of Aβ plaques illustrates a close proximal distribution of
microglia around the periphery and within AD Aβ plaques
(Figure 1C). Higher magnification of AD sections details
the association with Aβ plaques and activated microglia
(Figures 1A′–C′). Microglial bodies and processes are found
both surrounding and within the fibrillar corona region of the
AD plaques. Age-matched human control tissue (Figure 1D)
demonstrates IBA-1 positive microglial cells throughout the
cortical tissue in both ramified and active states. Human control
tissue does not exhibit microglial clustering as seen in the
AD tissue. The total amount of microglial staining in human
control tissue visually appears similar to AD tissue. Transgenic
APP/PS1 tissue exhibits both activated and ramified microglia
based on cellular morphology (Figure 1E). An association
between microglia and the periphery of Aβ plaques is observed
with activated microglia surrounding transgenic plaques
(Figures 1E–G, and magnification Figures 1E′–G′). Mouse
control tissue (Figure 1H) demonstrates sporadic ramified
microglial staining. There qualitatively appears to be similar
microglia staining in the mouse control tissue compared to that
of APP/PS1 tissue samples. Human and mouse control tissue did
not stain positive for thioflavin-S plaque formations (not shown).
Astrocyte IHC staining in AD tissue (Figure 2A) samples
illustrate GFAP positive cells throughout the microscopic
field and around the periphery of Aβ plaques (Figures 2B,C).
Astrocytes surround Aβ plaques rather than displaying a random
distribution throughout the cortex. Magnification of the AD
tissue demonstrates astrocyte dense arm morphology indicative
of an activated phagocytic astrocyte state (Figures 2A′–C′)
(Schubert et al., 2009). Astrocytic processes are radially
infiltrating into the halo region toward the core of the AD Aβ
plaques. Human control tissue (Figure 2D) illustrates astrocytes
in a traditional star pattern, with radiating processes typical of
astrocytes acting as neuronal metabolic helper cells. Transgenic
APP/PS1 mouse tissue sections exhibit an indiscriminate
distribution of GFAP positive astrocytes throughout the
microscopic field (Figures 2E–G). Magnification of Aβ plaques
in the APP/PS1 tissue demonstrates they are not surrounded
by GFAP positive astrocytes, but show a random staining
pattern (Figures 2E′–G′), converse to Alzheimer’s samples.
Mouse control tissue displays a similar GFAP positive astrocyte
distribution and reactive state to APP/PS1 tissue (Figure 2H).
Cells positive for light (L-) ferritin staining in AD tissue
(Figure 3A) are found in close proximity to thioflavin-S positive
Aβ plaques (Figures 3B,C) and throughout the cortical gray
matter field of view. The morphology of numerous L-ferritin
stained cells associated with Aβ plaques are similar to IBA-1
positive cells visualized in Figure 1, highlighting intracellular
L-ferritin within microglial cells. Closer magnification shows
that L-ferritin positive cells found within the coronal region
of the Aβ plaques are microglia (Figures 3A′–C′) based
on cellular morphology and prior research demonstrating
L-ferritin accumulation predominantly in AD microglia
(Kaneko et al., 1989; Grundke-Iqbal et al., 1990). Tri-staining
of L-ferritin, thioflavin-S, and IBA1 was not possible due
to overlapping fluorescent emission spectra of secondary
antibodies and thioflavin. L-ferritin immunoreaction visualized
in numerous small round cells dispersed throughout layers
of the entorhinal cortex are consistent with perivascular
oligodendrocyte morphology (Connor and Fine, 1986, 1987;
Connor et al., 1990). Human control tissue (Figure 3D) L-ferritin
immunoreactivity is primarily found in oligodendrocytes with
some microglial staining in a pattern consistent with aged
human gray matter (Connor et al., 1990). Positive L-ferritin
reactivity within the APP/PS1 tissue (Figure 3E) is found
in cells throughout the cortex and in relation to Aβ plaques
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FIGURE 1 | Ionized calcium-binding adaptor molecule - 1 (IBA-1)
antibody staining for microglia (red, A,E) and thioflavin-S (green,
B,F) for amyloid-β plaques in Alzheimer’s disease (A–C), APP/PS1
(E–G), control human (D) and control mouse (H) tissue samples at
100x (A–H) and 400x (A′–C′,E′–G′) magnification. Microglia in the
AD samples are associated with amyloid-β plaque location and are seen
in an activated amoeboid state surrounding plaques with processes
infiltrating into the coronal region. In the APP/PS1 tissue, microglial cells
are also observed in an activated state surrounding Aβ plaques. Human
control tissue samples show positive microglial staining and demonstrate
microglial cells in an intermediate ramified resting state with numerous
processes surrounding their somas. Mouse control tissue exhibits less
microglial staining overall and shows cells in a quiescent resting state.
The data demonstrates a subtle difference in microglial inflammatory
response between AD and APP/PS1 neural tissue samples. Scale bars
are 100 and 25µm in length.
(Figures 3F,G). Small round cells positive for L-ferritin
reflect previously described oligodendrocyte morphology in
both the transgenic APP/PS1 (Figure 3E) and control tissue
(Figure 3H). Higher magnification demonstrates L-ferritin
reactive cells within the core of Aβ plaques (Figures 3E′–G′).
While AD tissue shows a close morphological overlap of
microglia with IBA-1 and L-ferritin staining, it is not readily
apparent if the cells found within the APP/PS1 Aβ plaques
are microglia. Transgenic cells positive for L-ferritin outside
of the plaques appear within the granular layer of the cortex
and morphologically appear to be oligodendrocytes. A similar
distribution of L-ferritin immunoreactivity is visualized in the
mouse control tissue within oligodendrocyte cells (Figure 3H).
Intracellular heavy (H-) ferritin immunoreactivity, which
appears neuronal in origin, is found in cells throughout the AD
cortex (Figures 4A–C) (Thompson et al., 2003). Magnification
of Aβ plaques (Figures 4A′–C′) illustrates positive H-ferritin
staining within the plaque core which is absent from the halo
region. Human control tissue exhibited positive H-ferritin
staining of neuronal cells throughout the microscopic field of
view (Figure 4D). Intraneuronal staining for H-ferritin was
viewed in the APP/PS1 transgenic animals (Figure 4E) to a lesser
degree than AD samples. The relationship between H-ferritin
and the APP/PS1 Aβ plaques (Figures 4F,G) is realized at higher
magnification (Figures 4E′–G′), at which H-ferritin positive
immunoreactivity is found in the Aβ plaque core. Mouse control
tissue (Figure 4H) stained positive for intraneuronal H-ferritin
immunoreactivity throughout the microscopic field.
Frontiers in Neuroscience | www.frontiersin.org 5 July 2015 | Volume 9 | Article 255
Meadowcroft et al. AD and APP/PS1 histology
FIGURE 2 | Glial fibrillary acidic protein (GFAP) (red, A,E) for
astrocytes and thioflavin-S (green, B,F) staining for Aβ plaques in
Alzheimer’s disease (A–C), APP/PS1 (E–G), control human (D) and
control mouse (H) tissue at 100x (A–H) and 400x (A′–C′,E′–G′)
magnification. Astrocytes in the AD tissue are in a motile phagocytic state
and surround the coronal region of the Aβ plaques. In human control tissue,
the astrocytes are observed in their normal highly branched form indicative of
their supportive roll for neuronal tissue. APP/PS1 and mouse control tissue
similarly stain positive for GFAP throughout the tissue samples and illustrate
astrocytes in a highly branched normal supportive role. The strong
association seen between astrocytes and Aβ plaques in the AD tissue is not
seen in the transgenic model. The data indicates a differential astrocytic
inflammatory response to Aβ plaques in the natural AD milieu compared to
the transgenic model. The scale bars are standardized to 100 and 25µm.
Thioflavin-S staining (Figure 5A and higher magnification
in Figure 5A′) shows numerous dense core plaques throughout
the AD samples that stain positive for focal iron deposition
(red arrows). These iron stains can be seen in both the phase
contrast (Figures 5C,C′) and bright-field (Figures 5B,B′) images.
The phase contrast image shows the outline of the Aβ plaques as
opaque due to the light wave phase shift when passing through
the plaques. The APP/PS1 tissue exhibits positive thioflavin-S
staining for Aβ plaques (Figures 5F,F′), but does not exhibit focal
iron staining in either the phase contrast (Figures 5H,H′) or the
bright-field images (Figures 5G,G′). Positive iron staining was
found sporadically within the transgenic tissue, but did not co-
register to Aβ plaques (blue arrow) indicating positive Perl’s-DAB
staining. Similar to the human AD data, the APP/PS1 plaques
also exhibit a difference in light passage in the phase contrast
images. The phase contrast for the Alzheimer’s data shows a
close approximation of plaque size compared to the thioflavin-
S staining. Phase contrast images of the transgenic mouse tissue
demonstrate that Aβ plaques are larger in diameter than when
visualized with the thioflavin-S alone.
While the traditional Perl’s stain shows a lack of detectable
ferric iron in the APP/PS1 plaques, there is a minute amount of
iron associated with the transgenic Aβ plaques when stained with
a modified Perl’s stain and compared to the Alzheimer’s plaques
(Figures 5D,E,I,J). The modified iron stain incorporates protein
digestion of Aβ fibrils to enable the aqueous Perl’s iron stain
further access into the AD and APP/PS1 plaques. Treatment with
proteinase K results in the digestion of AD Aβ plaques causing
thioflavin-S negative staining for these plaques. This staining
result is presumably due to the degradation of the component
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FIGURE 3 | Light ferritin antibody (red, A,E) and thioflavin-S (green,
B,F) staining for amyloid-β plaques in AD (A–C), APP/PS1 (E–G),
control human (D) and control mouse (H) tissue at 100x (A–H)
and 400x (A′–C′,E′–G′) magnification. L-ferritin staining in the AD
tissue samples shows intracellular staining in cells surrounding amyloid
plaques and throughout the imaging field. The cellular morphology of
the L-Ferritin positive cells in the AD tissue is identical to the cells
stained for IBA-1 (see Figure 1 for comparison). Human control tissue
(D) L-ferritin reactivity is found in small round oligodendrocyte cells
throughout the cortex with some microglial staining consistent with aged
human gray matter. L-ferritin staining in the APP/PS1 tissue shows
intracellular staining of cells inside plaques and oligodendrocytes in the
granular layer of the cortex which. In contrast to the AD tissue, there is
no positive staining of cells surrounding amyloid plaques in the
APP/PS1 tissue samples. Mouse control tissue (H) demonstrates
intracellular L-ferritin reactivity in oligodendrocyte cells, similar to the
background oligodendrocyte staining in the APP/PS1 tissue. The scale
bars are set to 100 and 25µm in length.
Aβ fibrils resulting in an inability to intercalate the thioflavin-
S molecule(s). The modified Perl’s stain indicates the locations
of AD Aβ plaques based on iron staining morphology; the core
of the AD plaques is high in focal iron with less staining in the
coronal regions. The periphery of APP/PS1 plaques is moderately
digested, allowing thioflavin-S binding, illustrating a difference in
the ability of proteinase K to break down the transgenic plaques.
We hypothesize that this contrast is caused by the denser Aβ fibril
core composition of the transgenic plaques compared to the AD
plaques (Meadowcroft et al., 2009).
Aβ40 composition of plaques in relation to fibrillar thioflavin-
S stains are markedly different in AD than in APP/PS1 tissue
samples (Figure 6), with clear contrast in plaque morphology.
Thioflavin-S binding of AD plaques (Figures 6A,A′) shows a
dense fibrillar core surrounded by a large diffuse coronal halo
region. APP/PS1 thioflavin positive plaques (Figures 6D,D′)
exhibit a larger dense core region with a smaller diffuse
thioflavin-S positive coronal region. Fluorescent conjugated
Aβ40 antibodies bound to AD plaques (Figures 6B,B
′) stain
both the dense core and coronal regions for the 40 amino
acid Aβ variant, with a clear overlap of thioflavin-S staining
(Figures 6C,C′). APP/PS1 plaques exhibit Aβ40 protofibril
reactivity (Figures 6E,E′) that extends beyond the thioflavin
positive boundary of the large core and coronal regions
(Figures 6F,F′). This is similar to the results in Figure 5 where
phase contrast imaging of APP/PS1 tissue reveals diffuse amyloid
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FIGURE 4 | Heavy ferritin antibody (red, A,E) and thioflavin-S (green,
B,F) staining for amyloid-β plaques in AD (A–C), APP/PS1 (E–G),
control human (D) and control mouse (H) tissue at 100x (A–H) and
400x (A′–C′,E′–G′) magnification. H-ferritin staining of AD samples
demonstrates positive intracellular neuronal staining throughout the tissue
samples in relation to amyloid-β plaque core location. Human control tissue
(D) demonstrates positive H-ferritin staining in neurons throughout the
microscopic field. There was slight positive intraneuronal staining for H-ferritin
in the APP/PS1 tissue samples. H-ferritin positive immunoreactivity was
found in the core of APP/PS1 Aβ plaques. Mouse control tissue stained
positive for intraneuronal H-ferritin throughout the cortical tissue. Scale bars
are 100 and 25µm in length.
larger in diameter then the fibrillar thioflavin-S stain. Human
AD and APP/PS1 tissues both show positive intracellular Aβ40
reactivity in numerous cells outside of the plaques. Antibody
staining with Aβ42 (Figures 7B,B
′) shows that much of the
dense fibrillar core of the human plaques (Figures 7A,A′) is
composed of the 42 amino-acid Aβvariant, with some staining
in the coronal region (Figures 7C,C′ overlay). APP/PS1 tissue
did not stain inside or around the beta-amyloid plaques for
Aβ42 (Figures 7D–F, D–F
′). Apparent intracellular staining of
Aβ42 is found in numerous human AD cells throughout the
imaging field and is minimally found within the transgenic tissue
samples. It is important to note that the Aβ plaques in the
transgenic model are also recognized by human antibodies, as the
transcribed peptides are derived from humanmutations (Schwab
et al., 2004).
Alzheimer’s tissue exhibit positive FJC staining in both the
interior core of Aβ plaques and within cells outside of the coronal
halo regions (Figures 8A–C, 200x magnification). Additionally,
a precise overlap exists between FJC and Aβ40 staining in
numerous cells within the AD tissue (Figure 8A). In contrast,
positive FJC staining in APP/PS1 mouse tissue (Figures 8D–F)
samples is observed in the central core of Aβ plaques, while no
FJC or Aβ40 staining is seen in cells surrounding amyloid plaques.
Discussion
While regulation of iron has been shown to be associated with
the neurodegenerative processes in AD (Gerlach et al., 1994),
the causative relationship between disease pathology and iron
regulation has not been resolved. Previous work has determined
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FIGURE 5 | Alzheimer’s disease (A–E) and APP/PS1 (F–J) tissue
stained with thioflavin-S and a traditional Perl’s stain under
fluorescence (left), bright-field (middle), and phase contrast (right)
microscopy at 40x (A–J) and 200x (A′–H′) magnification. Red arrows
indicate selected plaques that have ferric iron associated with them, while
the blue arrow indicates a focal iron region not associated with an Aβ
plaque and is composed of hemosiderin or magnetite. The core of
numerous dense core Aβ plaques in the AD tissue samples exhibit focal
iron deposition and diffuse iron throughout their coronal regions in both
the phase contrast and bright-field image sets. The APP/PS1 transgenic
mouse tissue does not stain positive for focal iron associated with fibrillar
Aβ plaques with the Perl’s stain. The blue arrow illustrates a focal iron
deposit not associated with a plaque that indicates the Perl’s stain is
effective in staining ferric iron deposits. Phase contrast microscopy shows
regions where fibrillar thioflavin-s positive Aβ plaques are located, as well
as thioflavin-s negative regions beyond the fibrillar deposition. The
modified thioflavin-S and Perl’s stain use protein digestion to allow further
penetration of the aqueous stain into the hydrophobic AD (D,E) and
APP/PS1 (I,J) plaques. The stain indicates that there is a very minute
amount of iron found in the APP/PS1 plaques (J) that is not stainable with
traditional Perl’s staining methodology. Human plaques no longer stain
positive for thioflavin-S (D) due to Aβ protein degradation and subsequent
lack of thioflavin-S Aβ fibril intercalation, however the morphology of the
ferric iron staining verifies plaque location. There is a large visual amount
of iron in the core and halo region of the AD tissue (E) that is not seen
in the transgenic tissue. Scale bars are 250 and 50µm.
that metal ions play a role in Aβ fibril formation; however,
it is unclear how Aβ plaque aggregation is initiated. Aβ has
been characterized as a metalloprotein that binds Fe3+ and
the incorporation of the Aβ fibrils into plaque assemblies is
accelerated in an iron-enriched environment (Bush, 2002). Iron-
laden Aβ plaques are major sites for catalytic redox activity,
especially when combined with high concentrations of iron
(Huang et al., 1999; Sayre et al., 2000; Smith et al., 2000; Maynard
et al., 2005; Harman, 2006; Khan et al., 2006). Co-localization
of iron within Aβ plaques is accompanied by endoplasmic
reticulum stress induced apoptosis, DNA oxidation, and cellular
damage in cells adjacent to plaques (Atwood et al., 1999;
Perry et al., 2002; Lovell and Markesbery, 2007). Additionally,
in regions where Aβ plaques accumulate without the marked
presence of iron there is no indication of oxidative stress or
apoptotic activation (Ghribi et al., 2006); this contrast strongly
suggests that iron accumulation in and around plaques promotes
cellular damage. Furthermore, studies have demonstrated that
the toxicity of the Aβ peptide is amplified upon the direct
interaction of iron ions (Rottkamp et al., 2001). The escalated
presence of uncomplexed iron in the Alzheimer’s brain increases
the likelihood of an amyloid-iron interaction. This results in the
amplified production of hydroxyl and superoxide free radicals
through a Fenton–Haber/Weiss (respectively) reaction, which in
turn leads to neurotoxic oxidative stress in cells that are in close
proximity to Aβ plaques (Sayre et al., 1997). Numerous studies
support the hypothesis that oxidative damage surrounding the
Aβ plaques is involved in the neurodegenerative process of AD
(Sayre et al., 1997; Lovell and Markesbery, 2007).
There are numerous contrasts between cortical Aβ plaques
produced in AD and the APP/PS1 brains in terms of plaque
morphology, iron management, and related inflammation
(Table 2). Iron is frequently found in AD tissue samples, and
is notably concentrated within the central core, diffusely within
corona of the AD plaques, and throughout the tissue in the form
of focal hemosiderin or magnetite iron deposits as a result of
the breakdown of ferritin (Collingwood et al., 2008). In contrast,
the cortical plaques observed in the transgenic mouse tissue
contain trace amounts of diffuse iron; visibly less staining than
surrounding cortical cells (Figure 5).
Alzheimer’s Aβ plaques in this study exhibit a tight
association with cells containing L-ferritin, congruent with
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FIGURE 6 | Antibody stains for Aβ40 (red) and thioflavin-S (green)
of Alzheimer’s disease (A–C) and APP/PS1 (D–F) cortical tissue
viewed at 40x (A–F) and 100x (A′–F′) magnification. Aβ40 is found
within plaques in the AD and transgenic tissue samples as well as
intracellular staining throughout both samples. Thioflavin-S staining of
fibrillar Aβ demonstrates that the core of the AD plaques is composed
of highly fibrillar filaments. Antibody staining illustrates that the plaque
core contains Aβ40 with less staining in the coronal region. The
APP/PS1 tissue exhibits increased Aβ40 staining, indicating over
production of the 40 amino-acid constituent. APP/PS1 plaques also
display different morphology with a globular fibrillar structure that radially
extends from the center of plaque. Antibody staining with Aβ40
illustrates that the size of the APP/PS1 plaques is underestimated with
the fibrillar thioflavin-S stain alone as the antibody stains both fibrillar
and protofibril Aβ, demonstrating that the periphery of the transgenic
plaques is composed of protofibril filaments. This overestimation is
similar to the phase contrast images of APP/PS1 plaques in Figure 5.
Scale bars are 100 and 50µm.
FIGURE 7 | Antibody stains for Aβ42 (red) and thioflavin-S (green)
of Alzheimer’s disease (A–C) and APP/PS1 (D–F) cortical tissue
viewed at 40x (A–F) and 100x (A′–F′) magnification. Alzheimer’s
samples show positive Aβ42 staining in the core and coronal regions of
the plaques as well as intracellularly throughout the microscopic field.
The antibody stains indicate that the core and coronal regions of the
Alzheimer’s plaques are composed of both 40 and 42 amino-acid
variants; see Figure 6 for comparison. The APP/PS1 tissue stained
minimally for intracellular Aβ42, which was not associated with
transgenic plaques. The Aβ stains indicate that APP/PS1 plaques are
composed primarily of the 40 amino-acid constituent. Scale bar is
calibrated to 100 and 50µm.
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FIGURE 8 | Amyloid-β 40 staining (red) and Fluoro Jade-C (green)
staining in Alzheimer’s and APP/PS1 tissue sections at 200x
magnification. Aβ plaque staining is similar to that seen in Figure 6 for
both AD (A–C) and APP/PS1 (D–F) tissue samples with positive plaques
and intracellular Aβ40 staining. Fluoro Jade-C staining is positive for
degenerating neurons in the AD tissue sample and overlaps with
intracellular Aβ40 staining. The APP/PS1 tissue demonstrates fluoro
Jade-C positive staining within the core of the transgenic plaques and a
lack of staining for degenerating neurons surrounding plaques. The scale
bar is 50µm in length.
TABLE 2 | Summary of histological observations across tissue type.
Stain type Human–Alzheimer’s Mouse–APP/PS1
Iron High association of iron with plaques, diffuse staining throughout tissue Minimal staining, minute association with plaques
Aβ40 Core and coronal regions, close overlap with fibrillar thioflavin-S.
Staining of cells outside plaques
Highly positive, exhibit protofibril staining beyond Thio-S
boundary. Some staining of cells outside of plaques
Aβ42 Highly positive core, moderate staining in corona No positive staining
Plaque
Morphology
Small dense fibrillar core surrounded by diffuse coronal halo region Globular, large dense fibrillar core, small coronal region
Astrocyte High incidence of activated astrocytes around plaques Random distribution of resting—lack of association with plaques
Microglia Active microglia; close association around and inside of plaques Modest active and ramified, association with plaque periphery
L-Ferritin Throughout tissue and within coronal region of plaques—microglial
morphology with some oligodendrocyte
Found throughout. Not associated with plaques and
oligodendrocyte morphology
H-Ferritin Highly positive in plaque core and cells throughout cortex with random
distribution—neuronal in morphology
Minor positive staining in plaque core
Fluoro-jade C Positive staining in cells that express Aβ40. Some association
surrounding plaques
Central plaque core, no observable staining in plaque periphery
previous literature (Lopes et al., 2008). The cellular morphology
of L-ferritin positive cells is consistent with microglial IHC
staining; indicating that microglial cells surrounding and
infiltrating the plaques contain L-ferritin. Microglial and
oligodendrocyte cells are both known to stain positively
for L-ferritin (Connor et al., 1992b) and are differentiated
from one another based on previously determined signature
morphology (Lopes et al., 2008). Ferritin positive microglia
exhibit fine cytoplasmic ramifications and irregularly-shaped
elongated nuclei. Conversely, oligodendrocytes exhibit strong
parinuclear staining with few processes and a large nucleus
(Jellinger et al., 1990; Connor et al., 1992b; Lopes et al., 2008).
Furthermore, previous work has utilized L-ferritin staining as
a cellular marker for microglial cells (Kaneko et al., 1989)
and ferritin accumulation around neuritic plaques is almost
exclusively associated with microglial cells (Grundke-Iqbal et al.,
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1990). Microglial cells are known to harbor high quantities of
the light ferritin isoforms for long-term iron storage, understood
to be due to phagocytosis of apoptotic cells undergoing iron
induced free-radical oxidative stress (Connor et al., 1994; Han
et al., 2002; Mehlhase et al., 2006). In the APP/PS1 model, L-
ferritin staining is found throughout the tissue samples within the
granular cell layer and appears to be of oligodendrocyte origin
based on cellular morphology (Figures 1, 3, comparatively).
Having no light ferritin isoform associated with microglial cells
in the APP/PS1 model is indicative of a system that is not
undergoing excessive iron build-up. This finding is unlike the
AD tissue where microglial cells are responding to cell-mediated
inflammatory signaling and sequestering high amounts of iron
during the phagocytic process.
H-ferritin neuronal staining observed within AD tissue is
not detected to the same extent as within the transgenic mouse
tissue. H-ferritin rapidly sequesters iron and is involved in
excessive iron detoxification, thereby protecting against iron-
induced oxidative damage (Connor et al., 1994; Telfer and
Brock, 2002). Up-regulation of H- and L-ferritin transcription is
known to occur in relation to increased iron presence, hypoxic
incidents, as well as during enhanced inflammatory response
(Rogers et al., 2008); all of which are involved in the AD
process. The reduced inflammatory response and ferric iron
concentration found in the APP/PS1 neural tissue, compared
to the AD tissue, is consistent with the reduction of H-ferritin
staining. The data are congruent with an overabundance of iron
in the AD tissue and less global iron present in the APP/PS1
neural tissue.
Involvement of microglia and astrocytes is an important
component in the pathogenesis of AD as these cells respond
to neuronal environmental changes and produce numerous
regulatory proteins, inflammatory cytokines, and protease
inhibitors associated with inflammatory function (von Bernhardi
and Ramirez, 2001). Although generally considered a positive
presence during inflammatory response, there is growing support
that microglia play a detrimental role in the AD process (Wegiel
et al., 2000; von Bernhardi and Ramirez, 2001). The recruitment
and activation of microglial cells in and around Aβ plaques can
lead to the production of various cytokines and neurotoxins
that are known to cause neuronal injury and death (Benveniste
et al., 2001). A marked association is present between activated
microglial cells and Aβ plaques in the AD samples. Microglial
cells are seen surrounding and infiltrating the outer halo region
in close proximity to the dense core of the neuritic AD plaques.
Staining of the APP/PS1 tissue demonstrates an association
between microglial cells and amyloid plaques, however reduction
in ferritin staining within these microglia and lack of iron
staining within APP/PS1 plaques would indicate that they are
responding to the amyloid masses themselves, rather than
increased iron deposition.
The AD tissue samples exhibit a pronounced astrocytic
response with a clear relationship between plaque and astrocyte
location. Well defined astrocyte somas are found along the
periphery of the plaques with processes extending into the
coronal halo region. The APP/PS1 samples demonstrate strong
astrocyte staining throughout the tissue withminimal association
to Aβ plaques. Previous study has revealed increased astrocytosis
via cortical GFAP protein and mRNA measurement in whole
brain homogenates of the transgenic APP/PS1 mice (Gordon
et al., 2002; Gallagher et al., 2012). While the histological
data conceivably support increased astrocytosis; the whole brain
homogenates do not reflect the lack of an astrocyte and plaque
association as seen regionally on histological images of the
APP/PS1 tissue. Astrocytes are involved in the inflammatory
response found in regions of neural-cellular distress and
neurodegeneration; aiding in the distribution of metabolites
to facilitate the repair of affected regions. Astrocytes in the
AD tissue show a reduced star-like state with a large soma
and prominent processes, which is typical of an astrocyte in
response to cellular injury (Pekny and Nilsson, 2005; Schubert
et al., 2009), potentially induced by neurotoxic accumulation of
Aβ. In the transgenic model, the samples do not demonstrate
the same response and are viewed as resting astrocytes in a
metabolic helper state. It is of considerable interest that the
APP/PS1 tissue does not demonstrate an astrocyte and plaque
proximal relationship, yet exhibit microglia in close proximity
with the periphery of the Aβ plaques. Microglia in both the
AD and APP/PS1 tissue appear to be responding to the foreign
nature of the amyloid plaque masses in an attempt to scavenge
fibrillar beta-amyloid through phagocytosis (Koenigsknecht and
Landreth, 2004). The negative astrocytic response to Aβ plaques
in the APP/PS1 tissue is evidence of the lack of cellular
degradation surrounding these plaques. This observation is
furthered strengthened by the APP/PS1 FJC staining showing a
decreased amount of degenerating neurons surrounding plaques.
We hypothesize that astrocytes in the AD tissue are responding
to both Aβ and cellular oxidative distress related to focal iron
deposition. In addition, FJC staining of AD tissue shows a clear
overlap in neuronal degeneration staining with Aβ. It is not clear
from these stains if the cellular Aβ stained in the tissue samples is
intra- or extra-cellular in origin or the solubility of the Aβ, both of
which are associated with neuronal apoptosis (Kienlen-Campard
et al., 2002).
The co-occurrence of iron mismanagement and natural
production of aberrant Aβ fibrils in the AD brain are factors
that appear to aid in plaque formation in a yet to be determined
fashion. These factors are both markedly different in APP/PS1
neural tissue and it is plausible that the difference in amyloid fibril
production and ferric iron concentrations found in the transgenic
neural tissue partially account for the dissimilarity between AD
and transgenic tissue. Iron aids in Aβ fibrillogenesis in vitro
(Ryu et al., 2008) and it is hypothesized to play a role in in vivo
plaque generation. Increased amounts of iron present in the AD
brain along with fibrillogenic Aβ42 creates an environment suited
for plaque formation. It has also been proposed that peptide
sequences produced during APP cleavage act as a synergistic
neuronal iron mitigation system. This hypothesis is supported
by data showing that both APP and subsequent α-secretase
cleavage is modulated by iron levels (Bodovitz et al., 1995;
Avramovich-Tirosh et al., 2008; Carlson et al., 2008) and that
APP is involved in cellular ferroportin iron export (Duce et al.,
2010; Ayton et al., 2014; Wong et al., 2014). The APP/PS1 brain
stages a neural environment upon which Aβ plaques form that
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is dissimilar to the human AD brain. Our data provide evidence
of differential APP/PS1 plaque amyloid composition and iron
load compared to those found in AD tissue. Transgenic plaques
stained negatively for Aβ42 which is supported by the originators
of this APP/PS1 mouse line (Borchelt et al., 1997) who have
also shown reduced Aβ42 immunoreactivity. There also remains
the possibility that modifications to the C-terminus end of Aβ42
in the APP/PS1 model are present, which can affect plaque
morphology, iron-binding ability, and inhibit Aβ42 antibody
binding.
While the relation of iron to native APP processing, Aβ
generation, and amyloidogenesis is palpable, a clear causative
pathway has not been established. The seeding and growth
of beta-amyloid plaques in the human brain is influenced
by a myriad of factors, not limited to the influence of
transition metals (iron, copper, aluminum, and zinc), genetics,
and protein thermodynamics, all of which influence the
multifaceted AD process. As a concomitant loss of iron control
is not occurring in mouse brain tissue, the expression and
processing of endogenous APP is occurring differently. Increased
production of human APP and PS1 in the APP/PS1 model
is transgenetically modulated and transcription is controlled
by the native mouse prion protein promoter. As such, the
time course and evolution of AD and APP/PS1 Aβ plaques
is inherently different, with APP/PS1 plaque progression being
simplistic in comparison. In addition, the APP/PS1 mouse model
does not exhibit phosphorylated tau (pTau). The literature bases
provides indication of a relationship between iron and pTau
pathology whereupon iron chelation impedes the formation of
phosphorylated tau (Guo et al., 2013b); however, the role of pTau
pathology in the low iron environment of the transgenic brain is
unclear.
The present study outlines the association of iron content
with beta-amyloid plaques and postulates the effect of iron
on amyloidosis. With this imparted, the interpretations above
should be considered in the context of the wider literature
and how these relate to potential study confines. The literature
base contains some heterogeneity in regard to the effect of
formalin fixation on tissue iron content, specifically in brain
tissue. The data in the current study demonstrates that formalin
fixed human AD tissue exhibits more iron compared to APP/PS1
brain tissue, even with extended fixation of the human tissue.
The high binding affinity of beta-amyloid for iron (Jiang et al.,
2009) suggests that iron bound to the plaques remains largely
unaffected and that unbound iron makes the bulk of any leached
iron. Additionally, mouse regions known to have high iron
content, such as the substantia nigra, stained highly positive
for iron (not shown). Furthermore, the visual interpretation
of the histological results is qualitative in nature and care
must be taken when comparing these results to quantitative
metrics. Translation of the transgenic animal age to Alzheimer’s
tissue presents a challenge, especially in regard to late-stage
plaque progression. Evaluating aged APP/PS1 animals extends
the opportunity to study iron related plaque interactions in
late-stage plaques, similar to terminal AD patient tissue.
In summary, the data in this report provide evidence of
numerous contrasts between AD and the APP/PS1 transgenic
model aimed at mimicking the genesis of Aβ plaque formation.
It is largely unknown as to why human AD neuronal tissue
produces Aβ plaques, as the increase in the amyloidogenic Aβ
peptide pathway is multifaceted and represents a misregulation
of numerous endogenous systems. The current state of the
amyloid cascade hypothesis regards beta-amyloid as one of
many factors of the disease process (Pimplikar, 2009). For the
most part, the same complexity does not hold true for the
transgenic animal tissue for which Aβ and plaque formation is
governed by the increased production of two introduced human
mutations. The divergence between AD and APP/PS1 in plaque
iron, morphology, and inflammatory response suggest that the
transgenic model loosely fits within the current framework of the
amyloid cascade model (Hardy and Allsop, 1991). As such, the
differences between the plaques in the transgenic and AD tissue
sample are of considerable importance to researchers whom
are considering using the model for comparative Alzheimer’s
studies. The plaque deviations in the APP/PS1 model should be
taken into account when translating pharmacological or antibody
methodologies, such as iron chelation to mediate toxicity
(Guo et al., 2013a), the augmentation of the immune system’s
inflammatory response (Mengel et al., 2013), the alteration
of gamma and/or beta secretase mediated Aβ production
(Hajos et al., 2013), or clearance of the amyloid-β peptide
sequence (Malm et al., 2012). When interpreting results from
the transgenic model and translating these to human AD
trials, care must be taken to acknowledge the caveat that there
is considerable divergence between the APP/PS1 transgenic
model and AD with regard to iron concentration, inflammatory
response, and structural morphology associated with Aβ plaques.
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